Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23829970 | 1.00 | PGD (0.35) | PGDKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL30637871 | 0.81 | CYP2D6 (0.39) | — | |
| SCHEMBL28551189 | 0.75 | SLC22A6 (0.43) | PGDKDM4ELMNATSHR | |
| SCHEMBL8529276 | 0.75 | SLC22A6 (0.48) | PGDKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL9328721 | 0.75 | SLC22A6 (0.48) | PGDKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL6157808 | 0.75 | SLC22A6 (0.48) | PGDKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL28440042 | 0.71 | SLC22A6 (0.39) | PGDTSHR | |
| SCHEMBL3676474 | 0.69 | CA1 (0.39) | — | |
| SCHEMBL22409473 | 0.69 | CA1 (0.39) | — | |
| SCHEMBL29255184 | 0.69 | CA1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| WO-2021188414-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | HAVCR2, HDGF, HCCS | PGD 2679/4885KDM4E 1909/4885USP2 3334/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | PGD 2679/4885KDM4E 1909/4885USP2 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.